Does Cosentyx Interact with Methotrexate?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no clinically significant pharmacokinetic interactions with methotrexate (MTX), a common disease-modifying antirheumatic drug (DMARD). In studies, coadministration did not alter Cosentyx exposure or MTX levels.[1][2]
How Was the Interaction Studied?
A phase Ib open-label trial tested single-dose Cosentyx (150 mg subcutaneous) with and without weekly oral MTX (7.5-20 mg) in healthy males. Results found no changes in Cosentyx's maximum concentration (Cmax) or area under the curve (AUC), nor in MTX pharmacokinetics. Immunogenicity rates stayed low at 3%.[1]
Separate population pharmacokinetic analyses from psoriasis trials confirmed stable secukinumab clearance regardless of MTX use (up to 25 mg/week).[2]
Can They Be Used Together Safely?
Yes, guidelines support combination therapy for psoriatic arthritis. No dose adjustments are needed for either drug. European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) recommendations endorse IL-17 inhibitors like Cosentyx with MTX for inadequate responders to MTX alone.[3]
What Infections or Side Effects Increase with Combination?
Both suppress immunity—Cosentyx via IL-17 blockade, MTX via folate antagonism—raising infection risk. Upper respiratory infections occurred in 14-18% of combo users vs. 12-15% on Cosentyx alone in trials. Monitor for serious infections like candidiasis or tuberculosis reactivation; screen patients pre-treatment.[2][4]
No elevated hepatotoxicity or cytopenias reported specifically from interaction, but routine blood tests are standard with MTX.[3]
How Does This Compare to Other Biologics with Methotrexate?
Unlike some TNF inhibitors (e.g., adalimumab), where MTX reduces antidrug antibodies, Cosentyx has low immunogenicity even without MTX. Combo still improves efficacy in psoriatic arthritis (ACR20 response: 60-70% vs. 40-50% monotherapy).[2][5]
| Biologic | PK Interaction with MTX | Main Benefit of Combo |
|----------|--------------------------|-----------------------|
| Cosentyx | None | Efficacy boost, low antibodies |
| Humira | Minimal | Antibody reduction |
| Etanercept | None | Reduced immunogenicity |
Any Regulatory Warnings or Ongoing Studies?
Cosentyx prescribing information notes no MTX interaction but advises caution with live vaccines and immunosuppressants.[4] No dedicated post-marketing studies focus solely on this pair, but real-world data from registries like CorEvitas show similar safety profiles.[6]
[1] Clinical Pharmacology Study (PubMed)
[2] Cosentyx Label (FDA)
[3] EULAR/ACR PsA Guidelines (Rheumatology)
[4] Cosentyx EMA Summary
[5] PsA Trial Meta-Analysis (Lancet)
[6] CorEvitas PsA Registry Data